10 analysts have expressed a variety of opinions on Thermo Fisher Scientific TMO over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 3 | 2 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 4 | 3 | 1 | 0 | 0 |
3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts have recently evaluated Thermo Fisher Scientific and provided 12-month price targets. The average target is $634.5, accompanied by a high estimate of $670.00 and a low estimate of $610.00. Observing a 5.24% increase, the current average has risen from the previous average price target of $602.89.
Deciphering Analyst Ratings: An In-Depth Analysis
In examining recent analyst actions, we gain insights into how financial experts perceive Thermo Fisher Scientific. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Tycho Peterson | Jefferies | Raises | Buy | $650.00 | $600.00 |
Rajesh Kumar | HSBC | Raises | Buy | $670.00 | $660.00 |
Luke Sergott | Barclays | Raises | Equal-Weight | $615.00 | $590.00 |
Justin Bowers | Deutsche Bank | Raises | Buy | $610.00 | $600.00 |
Tycho Peterson | JP Morgan | Raises | Overweight | $650.00 | $600.00 |
Catherine Schulte | Baird | Lowers | Outperform | $620.00 | $621.00 |
Rajesh Kumar | HSBC | Raises | Buy | $660.00 | $630.00 |
Matthew Sykes | Goldman Sachs | Raises | Buy | $640.00 | $550.00 |
Vijay Kumar | Evercore ISI Group | Raises | Outperform | $610.00 | $575.00 |
Patrick Donnelly | Citigroup | Announces | Neutral | $620.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Thermo Fisher Scientific. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Thermo Fisher Scientific's stock. This comparison reveals trends in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Thermo Fisher Scientific's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Thermo Fisher Scientific analyst ratings.
Discovering Thermo Fisher Scientific: A Closer Look
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Key Indicators: Thermo Fisher Scientific's Financial Health
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Thermo Fisher Scientific's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -3.41% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Thermo Fisher Scientific's net margin is impressive, surpassing industry averages. With a net margin of 12.84%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Thermo Fisher Scientific's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.88% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Thermo Fisher Scientific's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.36% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Thermo Fisher Scientific's debt-to-equity ratio is below the industry average at 0.78, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.